加泰罗尼亚炎症性肠病的经济影响:基于人口的分析分析
Eduard Brunet-Mas1,2, Belen Garcia-Sagué1, Emli Vela3
1Servei d'Aparell Digestiu, Parc Taulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí (I3PT-CERCA), Departament de Medicina, Universitat Autònoma de Barcelona, Sabadell, Spain.
Therapeutic advances in gastroenterology
|February 15, 2024
概括
炎症性肠病 (IBD) 显著增加了医疗保健成本,患者患上更高的并发症和住院风险. 对IBD患者的年人均支出是非IBD个体的三倍以上.
科学领域:
- 胃肠病学 胃肠病学
- 卫生经济学 卫生经济学
- 公共卫生 公共卫生
背景情况:
- 炎症性肠病 (IBD) 对医疗保健系统造成了巨大的经济负担.
- 了解IBD的财务影响对于资源配置和政策制定至关重要.
研究的目的:
- 评估与IBD相关的当前医疗保健支出在加泰罗尼亚的一项全民研究中.
- 为了比较IBD和非IBD人群之间的医疗保健资源利用率和成本.
主要方法:
- 这是一项回顾性观察性研究,利用加泰罗尼亚卫生监测系统 (CHSS) 在2020年对700多万个人的数据进行了观察.
- 使用ICD-10-CM代码提取了关于医疗保健资源使用和经济影响的数据.
- 计算的医疗支出,并发症和住院费用,比较IBD患者与年龄,性别和收入调整的非IBD对照.
主要成果:
- 与非IBD群体相比,IBD群体表现出更高的并发症患病率和住院住院的风险增加了一倍.
- 对于IBD患者的医疗保健总支出达到1.64亿欧元,其中药房费用占60%.
- 平均年人均支出为IBD患者的4200欧元,而非IBD患者的1200欧元,克罗恩病 (CD) 的成本高于性结肠炎 (UC).
结论:
- 患有IBD的患者面临着明显更高的并发症风险和医疗保健资源利用率的增加.
- 患有IBD的人均医疗保健支出大约是没有IBD的人的3.4倍.
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
244
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
244
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
334
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
334
Inflammatory Bowel Disease I: Ulcerative Colitis
184
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
184
Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137


